Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label immunogenicity and safety study of subcutaneous Avonex in relapsing multiple sclerosis
2008-003098-42Phase 3Completed
- Sponsor
- Biogen
- Start
- Oct 2008
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of interferon beta-1a in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Development of neutralizing antibodies to interferon-beta. Started Oct 2008; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-003098-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003098-42.